Publication

Toward clinically applicable biomarkers for asthma: An EAACI position paper

Diamant, Z., Vijverberg, S., Alving, K., Bakirtas, A., Bjermer, L., Custovic, A., Dahlen, S-E., Gaga, M., van Wijk, R. G., Del Giacco, S., Hamelmann, E., Heaney, L. G., Heffler, E., Kalayci, O., Kostikas, K., Lutter, R., Olin, A-C., Sergejeva, S., Simpson, A., Sterk, P. J., Tufvesson, E., Agache, I. & Seys, S. F., Oct-2019, In : Allergy. 74, 10, p. 1835-1851 17 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Toward clinically applicable biomarkers for asthma: An EAACI position paper

    Final publisher's version, 1 MB, PDF document

DOI

  • Zuzana Diamant
  • Susanne Vijverberg
  • Kjell Alving
  • Arzu Bakirtas
  • Leif Bjermer
  • Adnan Custovic
  • Sven-Erik Dahlen
  • Mina Gaga
  • Roy Gerth van Wijk
  • Stefano Del Giacco
  • Eckard Hamelmann
  • Liam G. Heaney
  • Enrico Heffler
  • Omer Kalayci
  • Konstantinos Kostikas
  • Rene Lutter
  • Anna-Carin Olin
  • Svetlana Sergejeva
  • Angela Simpson
  • Peter J. Sterk
  • Ellen Tufvesson
  • Ioana Agache
  • Sven F. Seys

Inflammation, structural, and functional abnormalities within the airways are key features of asthma. Although these processes are well documented, their expression varies across the heterogeneous spectrum of asthma. Type 2 inflammatory responses are characterized by increased levels of eosinophils, FeNO, and type 2 cytokines in blood and/or airways. Presently, type 2 asthma is the best-defined endotype, typically found in patients with allergic asthma, but surprisingly also in nonallergic patients with (severe) asthma. The etiology of asthma with non-type 2 inflammation is less clear. During the past decade, targeted therapies, including biologicals and small molecules, have been increasingly integrated into treatment strategies of severe asthma. These treatments block specific inflammatory pathways or single mediators. Single or composite biomarkers help to identify patients who will benefit from these treatments. So far, only a few inflammatory biomarkers have been validated for clinical application. The European Academy of Allergy & Clinical Immunology Task Force on Biomarkers in Asthma was initiated to review different biomarker sampling methods and to investigate clinical applicability of new and existing inflammatory biomarkers (point-of-care) to support diagnosis, targeted treatment, and monitoring of severe asthma. Subsequently, we discuss existing and novel targeted therapies for asthma as well as applicable biomarkers.

Original languageEnglish
Pages (from-to)1835-1851
Number of pages17
JournalAllergy
Volume74
Issue number10
Publication statusPublished - Oct-2019

    Keywords

  • endotype, eosinophil, FeNO, IgE, phenotype, EXHALED NITRIC-OXIDE, NECROSIS-FACTOR-ALPHA, AIRWAY SMOOTH-MUSCLE, UNCONTROLLED PERSISTENT ASTHMA, PEDIATRIC SEVERE ASTHMA, DOUBLE-BLIND, CRTH2 ANTAGONIST, GENE-EXPRESSION, BRONCHIAL THERMOPLASTY, BASEMENT-MEMBRANE

ID: 101943291